Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
DDD.US
id: 1624
3D Systems ($DDD) Revenue Manipulation, False Guidance, and Regenerative Program Collapse Case
Investors can submit applications for the lead plaintiff role.
D. Delaware
Court1:25-cv-00734
Case number08/13/2024
Class period Start05/12/2025
Class period End08/12/2025
Lead Plaintiff motion deadline- $DDD investors filed a claim against 3D Systems for misleading the market about its revenue recognition practices, overstating its resilience to customer slowdowns, and concealing problems with its high-profile regenerative medicine program.
- After missing revenue expectations, adjusting milestone accounting, and withdrawing 2025 guidance, $DDD fell a combined 47.5%, including a 20.96% drop on March 27, 2025 and 26.6% on May 13, 2025.
Case Details:
Between August 13, 2024 and May 12, 2025, 3D Systems told investors it was executing a profitable growth strategy, supported by strong demand and long-term partnerships—especially a regenerative medicine deal with United Therapeutics to 3D print human lungs. Executives repeatedly claimed the company was well-positioned despite weak macro conditions.
In truth, the company was prematurely recognizing revenue from the regenerative medicine program using milestones that were later revised under pressure. Internally, management knew the revised criteria would delay revenue recognition and hurt performance, but failed to warn investors.
On March 26, 2025, 3D Systems announced a $9 million revenue reversal tied to the United Therapeutics deal. $DDD dropped 20.96% the next day. Then on May 12, 2025, the company posted a wider-than-expected loss, reported an 8% revenue decline, and withdrew 2025 guidance entirely. $DDD crashed another 26.6%.
Based on these events, $DDD investors filed a claim against 3D Systems, accusing the company of the following:
- It overstated resilience to customer weakness and concealed operational risks.
- It manipulated revenue recognition tied to a regenerative medicine contract.
Considering all the representations, investors believe 3D Systems misled the market about its revenue quality and business outlook to sustain its valuation.
Case Type
US Securities Class Action
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
05/08/2025
Filing date
06/13/2025
Lead Plaintiff Deadline
08/12/2025